News

According to Mucosis, the loan will be redeemed only if the FluGEM clinical development program is concluded successfully. Mucosis develops vaccines on the basis of its Mimopath technology,

The licenses granted to OMJ include worldwide licenses to Orexo’s ongoing OX-CLI and OX-ESI programs focusing on discovering and developing new small-molecule treatments for asthma, chronic obstructive pulmonary

The Phase 1/2 study is recruiting patients with advanced or treatment-refractory HCC. Patients in this trial are tested at entry for infection with hepatitis C virus (HCV). Although

Reportedly, all three presses are equipped with Prinect Inpress Control color measuring system, which controls color and register on the fly. A Speedmaster XL 105 press has been

The Ubichem isotope synthesis group has experience in the synthesis of labelled compounds for use by pharmaceutical and biotech companies in pharmacokinetic and metabolic studies, and will now

Angel Biotechnology said that the contract, for process development and GMP manufacture of specific antibodies, is valued at circa GBP1.3m. Work on the project is expected to start

The public-private partnership aims at taking advantage of the joint know-how in research and development of Sanofi-aventis and Charite to develop approaches faster and make them accessible to

Reportedly, Siegfried will carry out all required process transfer and manufacturing at Siegfried’s FDA and DEA registered site in Pennsville, New Jersey. Commercial manufacture of sodium oxybate is

Recently, Scottish Medicines Consortium (SMC) has accepted the use of Novartis’ omalizumab for children in Scotland aged 6 to 11 years with severe, persistent allergic asthma who are